First Clinical Study of the Selective 5-HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache
Article first published online: 20 MAY 2005
Headache: The Journal of Head and Face Pain
Volume 31, Issue 5, pages 296–297, May 1991
How to Cite
Couturier, E.G.M., Hering, R., Foster, C.A., Steiner, T.J. and Rose, F. C. (1991), First Clinical Study of the Selective 5-HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache. Headache: The Journal of Head and Face Pain, 31: 296–297. doi: 10.1111/j.1526-4610.1991.hed3105296.x
- Issue published online: 20 MAY 2005
- Article first published online: 20 MAY 2005
- Accepted for Publication: April 6, 1991.
- Cited By
- acute migraine
SYNOPSISGranisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.